DERIVO® 2heal® Study: Clinical Safety and Efficacy of the DERIVO® 2heal® Embolisation Device

RecruitingOBSERVATIONAL
Enrollment

158

Participants

Timeline

Start Date

December 15, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Intracranial AneurysmFlow Diverter
Interventions
DEVICE

Flow Diverter Treatment with DERIVO 2 Heal Embolisation Device

Flow diversion therapy fpr intracranial aneurysm treatment.

Trial Locations (17)

Unknown

RECRUITING

Universitätsklinikum Augsburg, Augsburg

RECRUITING

Charité - Universitätsmedizin Berlin, Berlin

RECRUITING

Klinikum Bremerhaven-Reinkenheide, Bremerhaven

RECRUITING

Universitätsklinikum Köln, Cologne

RECRUITING

Universitätsklinikum Carl Gustav Carus Dresden, Dresden

RECRUITING

Universitätsklinikum Düsseldorf, Düsseldorf

RECRUITING

Universitätsklinikum Essen, Essen

RECRUITING

Krankenhaus Nordwest Frankfurt, Frankfurt am Main

RECRUITING

Universitätsmedizin Halle, Halle

RECRUITING

Universitätsklinikum Hamburg-Eppendorf, Hamburg

RECRUITING

Westpfalz-Klinikum Kaiserslautern, Kaiserslautern

RECRUITING

Universitätsklinikum Magdeburg, Magdeburg

RECRUITING

"Mühlenkreiskliniken , Johannes Wesling Klinikum Minden"

RECRUITING

Ludwig-Maximilians-Universität München, München

RECRUITING

Technische Universität München, München

RECRUITING

Klinikum Vest - Knappschaftskrankenhaus Recklinghausen, Recklinghausen

RECRUITING

Städtisches Klinikum Solingen, Solingen

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Acandis GmbH

INDUSTRY

NCT05543447 - DERIVO® 2heal® Study: Clinical Safety and Efficacy of the DERIVO® 2heal® Embolisation Device | Biotech Hunter | Biotech Hunter